The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CRLBF | -25.41% | -83.78% | -30.47% | -72% |
| S&P | +16.9% | +95.99% | +14.39% | +152% |
Cresco Labs Inc. engages in cultivating medical grade cannabis, manufacturing medical products derived from cannabis cultivation, and distributing such products to medical or adult use consumers. It focuses on regulatory compliance while working to develop condition-specific strains of cannabis and non-invasive delivery methods. The company was founded by Charles Bachtel, Joseph Caltabiano, Dominic Sergi, Rob Sampson, and Brian McCormack on July 6, 1990 and is headquartered in Chicago, IL.
Here's what you need to know about the top CBD stocks.
The veteran cannabis company is gamely facing the many challenges of its business.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $163.62M | -11.2% |
| Gross Profit | $79.43M | -11.3% |
| Gross Margin | 48.54% | -0.1% |
| Market Cap | $182.49M | -66.7% |
| Market Cap / Employee | $0.06M | 0.0% |
| Employees | 2.9K | 5.1% |
| Net Income | -$13.89M | 72.9% |
| EBITDA | $40.18M | -17.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $149.76M | 29.2% |
| Accounts Receivable | $39.49M | -27.2% |
| Inventory | 89.2 | -6.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $607.47M | -7.8% |
| Short Term Debt | $23.43M | 2.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -3.38% | 8.6% |
| Return On Invested Capital | -15.07% | 1.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$4.10M | -139.3% |
| Operating Free Cash Flow | $9.37M | -44.1% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.24 | 0.70 | 0.53 | 0.39 | -63.51% |
| Price to Sales | 0.79 | 0.44 | 0.36 | 0.27 | -63.24% |
| Price to Tangible Book Value | -5.03 | -2.60 | -2.47 | -1.58 | -78.29% |
| Price to Free Cash Flow TTM | 7.40 | 2.89 | 2.44 | 2.06 | -75.84% |
| Enterprise Value to EBITDA | 22.25 | 20.78 | 23.02 | 14.42 | -30.47% |
| Free Cash Flow Yield | 13.5% | 34.5% | 41.0% | 48.5% | 313.94% |
| Return on Equity | -14.0% | -15.2% | -17.3% | -10.0% | -68.32% |
| Total Debt | $690.45M | $639.64M | $645.73M | $630.91M | -7.51% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
